IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 462 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5496    
    Printed189    
    Emailed4    
    PDF Downloaded166    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 

 RESEARCH PAPER
Year : 2005  |  Volume : 37  |  Issue : 5  |  Page : 320-324

"Quick Cycle" neoadjuvant chemotherapy in squamous cell carcinoma of cervix


1 Department of Obstetrics & Gynecology, Dayanand Medical College &Hospital, Ludhiana, Punjab, India
2 Department of Obstetrics and Gynecology, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
3 Department of Pathology, University College of Medical Sciences & Guru Teg Bahadur Hospital, Delhi, India
4 Specialty Ranbaxy, Mumbai, Maharashtra, India

Correspondence Address:
Shalini Rajaram
B-704 Gitanjali Apartments, Vikas Marg Extension, Delhi-110 092
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.16857

Rights and Permissions

Objective: To evaluate the efficacy and safety of a 'Quick cycle' neoadjuvant chemotherapeutic regime in squamous cell carcinoma (SCC) of cervix and monitor the response to chemotherapy using Squamous Cell Carcinoma Antigen (SCC-Ag) as tumor marker. Materials and Methods: Thirty patients with SCC of cervix (Stage I-IV) entered the study to receive three courses of multiagent neoadjuvant chemotherapy (vincristine, cisplatin and bleomycin) in a weekly regime. SCC-Ag was evaluated in these patients' pre and post-chemotherapy. Results: Patients with stage IB2 had a complete response and two of seven patients with stage IIB became operable. The overall response rate was 47.8% and complete response rate was 8.7%. Decrease in tumor volume post-chemotherapy was significant (P<0.002). Toxicity including myelosuppression was minimal. A statistically significant decrease in SCC-Ag (stage II and III) was seen post-chemotherapy (P <0.04 and 0.005, respectively). Conclusion: The weekly chemotherapeutic regime was found to be safe and effective and SCC-Ag is a useful tumor marker for monitoring response to chemotherapy.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow